Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2020, with the report dated March 2, 2020. The filing serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification rather than a financial performance report.
| Capital Metric | Value |
|---|---|
| Issued Share Capital (as of Feb 28, 2020) | 5,384,724,777 Ordinary Shares (25 pence each) |
| Treasury Shares | 367,705,950 |
| Total Voting Rights | 5,017,018,827 |
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It solely updates the denominator for shareholder interest calculations based on the share capital status as of February 28, 2020.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The primary purpose is to inform shareholders of the total voting rights figure to be used for determining notification requirements under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,017,018,827) for compliance with FCA disclosure thresholds.
- Confirm the number of shares held in Treasury (367,705,950) to understand the difference between issued capital and voting rights.
- Note that this filing does not contain financial results; investors should refer to Form 20-F or quarterly earnings releases for performance data.